Porcine factor VIII therapy in patients with factor VIII inhibitors

  • Charles Hay
  • Jay N. Lozier
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 386)


A review is presented of the use of porcine factor VIII (F.VIII) in patients with F.VIII inhibitors and acquired or congenital hemophilia. This review is drawn partly from the published literature and partly from an international survey of the use of porcine F.VIII in patients with congenital hemophilia conducted under the auspices of the ISTH F.VIII and IX scientific standardization subcommittee. The treatment of congenital and acquired hemophilia are compared, since they differ in a number of important respects.


Platelet Count Factor VIII Bleeding Episode Home Therapy Inhibitor Titer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kernoff PBA, Thomas ND, Iilley PA, Clinical experience with polyelectrolytefractionated porcine FVIII concentrate in the treatment of haemophiliacs with antibodies to factor VIIL Blood 1984, 63; 31 – 41.Google Scholar
  2. 2.
    Gatti L, Mannucci PM, Use of porcine factor VIII in the management of seventeen patients with FVIII antibodies. Thrombosis and Haemostasis 1984, 51; 379 – 392.PubMedGoogle Scholar
  3. 3.
    Brettler DB, Forsberg A, Levine PH, et al.. The use of porcine factor VIILC in the treatment of patients with inhibitor antibodies to VIILC: A multicenter US trial. Arch intern Med 1989, 149; 1381 – 1385.PubMedCrossRefGoogle Scholar
  4. 4.
    Morrison AE, Ludlam CA, Kessler C, Use of porcine factor VIII in the treatment of patients with acquired hemophilia. Blood 1993, 81; (6): 1513–1520.Google Scholar
  5. 5.
    Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982, 60; 1103 – 9.PubMedGoogle Scholar
  6. 6.
    Lozier JN, Santagostino E, Kasper CK, Teitel JM, Hay CRM, The use of porcine factor VIII for surgical procedures in haemophilia A patients with inhibitors. Seminars in Hematology, 1993, 30; (2): supp 1; 10–21.Google Scholar
  7. 7.
    Hay CRM, Laurian Y, Verroust F, Preston FE, Kernoff PBA, Induction of immune tolerance in patients with haemophilia A and inhibitors treated with porcine factor VIIIC by home therapy. Blood 1990, 76; 882 – 886.PubMedGoogle Scholar
  8. 8.
    Gringeri A, Santagostino E, Tradati F, Giangrande PLF, Mannucci PM, Adverse effects of treatment with porcine factor VIIL Thrombosis and Haemostasis 1991, 65; 245 – 247.Google Scholar
  9. 9.
    . Kernoff PBA, The factor Vlll-related antigen and antibodies to factor VIII. MD Thesis, University of London 1974.Google Scholar
  10. 10.
    Altieri DC, Capitanio AM, Mannucci PM, Von Willebrand factor contaminating porcine factor VIII concentrate (Hyate:C) causes platelet aggregation. Brit J Haematol 1986, 63, 703 – 711.CrossRefGoogle Scholar
  11. 11.
    Fukui H, Yoshioka A, Shima M, Mori K, Yorifuji H, et al. Multicenter clinical trial of a highly purified porcine factor VIII concentrate (MTI-9002 (Hyate.C)) in haemophilia A patients with inhibitors. Japanese J Thrombosis and Haemostasis 1991,2; (6): 487–50.Google Scholar

Copyright information

© Plenum Press, New York 1995

Authors and Affiliations

  • Charles Hay
    • 1
  • Jay N. Lozier
    • 2
  1. 1.Liverpool University Department of HematologyRoyal Liverpool University HospitalLiverpoolUK
  2. 2.Department of Medicine, Division of HematologyUniversity of North Carolina School of MedicineChapel HillUSA

Personalised recommendations